Skip to main content

Table 2 Comparison of mean dosimetric parameters computed for 3D-CRT, TD, B-VMAT, VMAT and HT

From: Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations

Variable

Objectives

3D-CRT

TD

B-VMAT

VMAT

HT

PTV

 

Volume (cm3)

428.7 ± 195.6

DMean

30

30.6±0.7b,e

30.0±0.1a,c,d

30.4±0.2b,e

30.4±0.2b,e

29.9±0.1a,c,d

V90% (%)

99

98.2±1.0b,d,e

99.2±0.7a,c,d

98.3±1.2b,e

98.6±1.1b,e

99.1±0.2a,c,d

V95% (%)

95

94.8±0.5b,d,e

97.4±1.7a,c,d,e

95.5±2.3b

95.4±1.7b

95.9±0.7a,b

V107% (%)

<1

5.0±5.2b,d,e

0.02±0.03a,c,d,e

5.5±3.8b,e

5.50±3.80b,e

0.3±0.28a,b,c,d

CN95% (%)

1

0.30±0.1c,d,e

0.30±0.1c,d,e

0.67±0.1a,b,d,e

0.76±0.02a,b,c

0.77±0.06a,b,c

HI

0

0.30±0.1b,c,d,e

0.10±0.03a,c,d,e

0.20±0.1a,b,e

0.16±0.04a,b,e

0.07±0.01a,b,c,d

Lung

 

Dmean(Gy)

-

6.6±2.6

6.3±2.7

5.9±2.5

6.4±2.5

5.9±2.2

V5Gy (%)

50

29.3±12.4b,c,d,e

26.4±11.6a,c,d,e

31.3±14.3a,b,d,e

39.0±15.6a,b,c

37.0±12.6a,b,c

V10Gy (%)

33

22.6±9.4d

21.9±9.6d

20.8±10.0d

25.6±13.3a,b,c,e

20.6±11.0d

V15Gy (%)

-

18.6±7.6c,d,e

18.5±8.2c,d,e

15.3±8.0a,b,e

15.0±10.6a,b,e

12.8±7.5a,b,c,d

V20Gy (%)

-

15.2±6.2c,d,e

15.6±6.9c,d,e

11.3±6.7a,b,d,e

8.8±6.3a,b,c,

7.6±4.5a,b,c

V30Gy (%)

-

3.5±2.7b,c,d,e

0.7±0.5a

0.8±0.8a

0.3±0.3a

0.1±0.3a

Breast

 

Dmean(Gy)

-

1.0±0.4c

0.9±0.9c

0.7±0.3a,b,d,e

0.9±0.4c

1.2±0.9 c

V4Gy (%)

50

4.5±2.3d,e

3.7±4.2d,e

4.6±3.0d,e

6.2 ±4.7a,b,c

5.4±5.5a,b,c

V10Gy (%)

33

2.5±1.4c,d,e

2.4±3.0c,d,e

1.1±1.0a,b

1.2±1.1a,b

1.4±1.8a,b

V15Gy (%)

-

1.4±0.7c,d,e

1.6±2.2c,d,e

0.4±0.4a,b

0.3±0.4a,b

0.6±1.0a,b

V20Gy (%)

-

0.9±0.5c,d

1.3±1.9c,d

0.1±0.1a,b

0.1±0.1a,b

0.2±0.5a,b

V30Gy (%)

-

0.2±0.3c,d,e

0.6±1.0c,d,e

0a,b

0a,b

0a,b

Thyroid

 

Dmean(Gy)

-

17.7±4.5c,d,e

17.3±5.1c,d,e

13.5±6.3a,b

13.5±5.3a,b

14.4±5.5a,b

V18Gy (%)

50

45.9±18.1c,d,e

51.3±19.2c,d,e

35.2±21.6a,b

33.4±18.8a,b

38.2±23.0a,b

V25Gy (%)

33

32.0±14.4c,d,e

32.9±14.6c,d,e

22.2±15.8a,b

21.3±14.7a,b

24.5±19.8a,b

Coronary Ostia

 

Dmean(Gy)

-

22.1±9.9c,d,e

19.8±9.3c,d,e

15.7±7.9a,b

15.9±8.9a,b

16.4±8.4a,b

V20Gy (%)

100

73.5±40.8c,d,e

59.1±37.7c,d,e

43.1±32.6a,b

44.0±34.3a,b

44.3±34.2a,b

Heart

 

Dmean(Gy)

-

5.1±4.0c,d,e

4.3±3.7c,d,e

3.5±2.3a,b

3.1±2.2a,b

3.8±3.8a,b

Non target tissue

 

Dmean(Gy)

-

4.1±1.3

3.8±0.9

3.1±0.7

3.6±0.9

3.90±0.96

Time (min)

-

3.2±1.1b,c,d,e

4.4±1.1a,c,d,e

12.0±2.8a,b,d,e

6.2±1.3a,b,c,e

7.2±1.6a,b,c,d

  1. Statistically significant differences (p<0.05) for each technique versus alternatives are reported: aTest vs 3D-CRT; b Test vs TD; c Test vs B-VMAT; d Test vs VMAT; e Test vs HT.